D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study by G. Palareti et al.
Vol.:(0123456789) 
Internal and Emergency Medicine (2020) 15:453–462 
https://doi.org/10.1007/s11739-019-02216-y
IM - ORIGINAL
D‑dimer testing, with gender‑specific cutoff levels, is of value 
to assess the individual risk of venous thromboembolic recurrence 
in non‑elderly patients of both genders: a post hoc analysis 
of the DULCIS study
Gualtiero Palareti1  · Cristina Legnani1 · Emilia Antonucci1 · Benilde Cosmi2 · Daniela Poli3 · Sophie Testa4 · 
Alberto Tosetto5 · Walter Ageno6 · Anna Falanga7 · Piera Maria Ferrini8 · Vittorio Pengo9 · Paolo Prandoni1 · for the 
DULCIS (D-dimer and ULtrasonography in Combination Italian Study) Investigators
Received: 23 August 2019 / Accepted: 11 October 2019 / Published online: 5 November 2019 
© The Author(s) 2019
Abstract
Male patients, especially the young, are at a higher risk of recurrent venous thromboembolism (RVTE) than females. Recent 
scientific reports show the use of D-dimer does not help predict RVTE risk in males. In the present report, we reviewed the 
data obtained in the DULCIS study (main report published in Blood 2014), focusing on D-dimer results recorded in non-
elderly patients of both genders included in the study, and their relationship with RVTE events occurring during follow-up. 
Using specifically designed cutoff values for positive/negative interpretation, serial D-dimer measurements (performed 
during warfarin treatment and up to 3 months after discontinuation of anticoagulation) in 475 patients (males 57.3%) aged 
≤ 65 years were obtained. D-dimer resulted positive in 46.3% and 30.5% of males and females, respectively (p = 0.001). Fol-
lowing management procedure, anticoagulation was stopped in 53.7% of males and 69.5% of females, who had persistently 
negative D-dimer results. The rate of subsequent recurrent events was 1.7% (95% CI 0.5–4.5%) and 0.4% (95% CI 0–2.5%) 
patient-years in males and females, respectively, with upper limits of confidence intervals always below the level of risk 
considered acceptable by international scientific societies for stopping anticoagulation (< 5%). In conclusion, using sensi-
tive quantitative assays with specifically designed cutoff values and serial measurements during and after discontinuation of 
anticoagulation, D-dimer testing is useful to predict the risk of RVTE and is of help in deciding the duration of anticoagula-
tion in both male and female adult patients aged up to 65 years.
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Introduction
A first venous thromboembolic (VTE) event, presenting 
as deep vein thrombosis (DVT) and/or pulmonary embo-
lism (PE), tends to recur after anticoagulation treatment is 
stopped. However, the risk of recurrence is not the same in 
all patients and varies greatly in relation to the nature of 
index event (unprovoked, or associated with permanent or 
transient risk factors), and to the characteristics of patients 
[1]. Males have consistently been found to be at a higher risk 
of recurrent VTE than females [2–7].
D-dimer testing, performed during or after cessation of 
anticoagulant treatment, has been proposed as a means to 
help assess the risk of recurrence in adult outpatients with 
unprovoked or minimally provoked VTE, which is higher 
in cases with positive D-dimer [4, 8, 9]. However, in other 
studies negative D-dimer results failed to reliably predict the 
risk of recurrence in male patients, being associated with a 
higher than acceptable rate of recurrence in these patients 
[3, 10]. In these results, D-dimer testing was excluded from 
The members of the original DULCIS study group are listed in 
acknowledgements section.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1173 9-019-02216 -y) contains 
supplementary material, which is available to authorized users.
 * Gualtiero Palareti 
 gualtiero.palareti@unibo.it
Extended author information available on the last page of the article
454 Internal and Emergency Medicine (2020) 15:453–462
1 3
a prediction model (the HERDOO2, [3]), or considered of 
limited value to be used in men, for making a decision on 
the duration of anticoagulation after a first unprovoked VTE 
[10, 11].
In the present report we re-analyzed the data recorded in 
the DULCIS study [12], with a view to assessing whether 
or not D-dimer results can be of help to guide decisions on 
the duration of anticoagulation in male and female patients. 
The prevalence of negative/positive D-dimer results in 
male or female patients aged 65 years or less included in 
the DULCIS was calculated, as well as the predictive value 
of D-dimer results for recurrent events in patients who did 
not resume anticoagulation because of persistently negative 
D-dimer results or because they refused to do so notwith-
standing the occurrence of positive D-dimer results. For 
several reasons, we decided to limit our analysis to patients 
aged up to 65 years. It is well known, in fact, that D-dimer 
levels increase physiologically in elderly patients [13] which 
is why reliable cut-off values to be used for prediction of 
the risk of recurrent VTE events are currently not available. 
Furthermore, it has been shown that a prediction model that 
included D-dimer levels had a low discriminative ability 
in patients aged > 65 years whose risk of recurrence was 
reported to be the same, regardless of D-dimer levels [14]. 
We believe that the decision on prolonged anticoagulant 
treatment in the elderly should be driven by the individual 
perceived risk/benefit ratio, paying more attention to the risk 
of bleeding than to the estimated risk of VTE recurrence.
Materials and methods
The DULCIS study
As detailed elsewhere [12], DULCIS was a multicenter 
prospective study involving a cohort of 1010 patient of 
both sexes, aged ≥ 18 years, with a median age (IQR) of 
67 (51–77) years, who had suffered a first VTE (proximal 
DVT of the legs, PE, or both) objectively diagnosed by 
compression ultrasonography of deep leg veins, computed 
tomographic pulmonary angiography or ventilation/perfu-
sion lung scan, as appropriate. This trial was registered at 
http://www.clini caltr ials.gov as NCT00954395. Patients 
were eligible if the index event was either idiopathic or asso-
ciated with weak risk factors (the list of weak or strong risk 
factors is reported in Table 1 Supplementary), and if they 
had completed at least 3 months of therapy with a vitamin K 
antagonist (VKA)—the only oral anticoagulant drug avail-
able at the time for long-term VTE treatment—with a target 
International Normalized Ratio (INR) of 2.5 (range 2.0–3.0 
INR). The screened patients were examined to assess pres-
ence of inclusion/exclusion criteria (listed in Table 2S), with 
a view to avoiding inclusion of patients who were true can-
didates for short or extended anticoagulation, according to 
the available international guidelines [15].
Before inclusion, and after at least 3 months of anti-
coagulation, all patients received a bilateral compres-
sion ultrasonographic (CUS) examination of the proximal 
deep veins. Patients with detected residual vein thrombo-
sis (RVT; > 4-mm vein diameter at probe compression in 
the transverse section) were invited to complete a total of 
12 months VKA therapy before inclusion in the study.
D‑dimer assessment
D-dimer, the final degradation product when plasmin 
degrades the crosslinked fibrin, is interpreted as a marker 
of coagulation activation. The measurement of D-dimer 
plasma levels has been validated for the exclusion of VTE 
in symptomatic patient populations and in the diagnosis and 
monitoring of coagulation activation in disseminated intra-
vascular coagulation. More recently, D-dimer assays proved 
clinically useful in the prediction of recurrent VTE and risk 
stratification of patients for VTE recurrence [16]. To this 
end, D-dimer plasma levels have been measured either dur-
ing anticoagulant treatment [3] and/or after its discontinu-
ation [4, 8, 9, 12]. D-dimer results have also been included 
in risk assessment scores proposed to predict the individual 
risk of recurrence after unprovoked VTE [5, 6].
For the present report, D-dimer levels were assessed 
using the quantitative assay routinely used in each partici-
pating center, provided it was one of those listed in Table 1; 
the table also shows corresponding cutoff values used to 
define positive or negative results in males or females aged 
Table 1  Sex-specific cutoff 
levels for different D-dimer 
assays adopted in the DULCIS 
study for patients aged 70 years 
or less
Commercial D-dimer assay (manufacturer) Males Females Cutoff values currently recom-
mended by manufactures for VTE 
exclusion
VIDAS D-dimer Exclusion (bioMerieux), ng/mL 490 600 500
Innovance D-dimer (Siemens), mg/L 0.500 0.550 0.500
HemosIL D-dimer (Werfen), ng/mL 205 225 230
HemosIL D-dimer HS (Werfen), ng/mL 170 215 230
STA Liatest D-dimer (Diagnostica Stago), μg/mL 0.340 0.450 0.500
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70 years or less (the patients involved in the present analy-
sis were aged up to and including 65 years). Age- and sex-
specific cutoff values were defined on the basis of a previous 
study [17], often differing from those recommended by the 
manufacturers for VTE exclusion and generally being lower 
in males than in females. Recurrent VTE and death caused 
by VTE were the main study outcomes, after evaluation by 
a central adjudication committee whose members were una-
ware of patient name, D-dimer testing results at inclusion, 
management, or enrolling center.
The included patients underwent serial D-dimer assess-
ment starting at baseline during anticoagulation (T0). 
Patients with positive baseline D-dimer (the criteria are 
indicated below) were recommended to continue antico-
agulation, whereas those with negative D-dimer were asked 
to stop VKA and repeat D-dimer testing after 15, 30, 60 
and 90 days after baseline; patients were also told that at 
first positive D-dimer result, oral anticoagulation resumption 
would be recommended. The study protocol was approved 
by the local ethics committees and was conducted in accord-
ance with the Declaration of Helsinki. Written informed 
consent was collected according to local practice.
Statistical analysis
Descriptive analysis, expressed as median and interquartile 
range, was used. Differences between groups were assessed 
using the X2 test with Yates’ correction for categorical vari-
ables and the Mann–Whitney U test for continuous vari-
ables. Incidence rates of adverse events were calculated both 
as the number of events per 100 patients examined and the 
number of events per 100 patient-years (% patient-year) of 
observation. Kaplan–Meier survival curves were plotted to 
estimate the cumulative incidence of symptomatic recurrent 
VTE. A univariate Cox regression analysis was conducted 
to evaluate the relationship between the recurrent events in 
males and females and positive or negative D-dimer results; 
hazard ratios (HR) and their 95% CIs were calculated. The 
data were analyzed with the use of Prism software (Version 
3.0, GraphPad Software Incorporated, San Diego, CA) and 
SPSS software (version 11.0 SPSS Inc., IBM, Armonk, NY).
Results
The present analysis re-examined only the data of non-
elderly patients [aged up to 65 years, median age 44 years 
(IQR 36–51)—totaling 475 with 272 males (57.3%)]—
included in the DULCIS study [12] after a first sympto-
matic VTE episode. Table 2 shows patient profiles. Women 
were significantly younger than males (p < 0.0001), with an 
index event that was more often an isolated PE (p = 0.001). 
The large majority of males (88.2%) had an event that 
was idiopathic, whereas most females (69.0%, p < 0.0001) 
presented events that were associated to a weak risk fac-
tor, mainly hormonal contraceptive therapy (HCT, 59.1%). 
Males frequently had greater persistent residual vein throm-
bosis than females (RVT, 13.6% vs 3.0%, p = 0.0001), and 
more often received anti-platelet treatment (5.9% vs 1.0%, 
p = 0.006).
 After serial assessment, D-dimer testing resulted positive 
in 188 patients (39.6%) and negative in the remainder. Alto-
gether, D-dimer assay was positive in 126 (46.3%) males 
and in 62 (30.5%) females (p = 0.001) (Table 3). The preva-
lence of first-time-ever positive D-dimer results in males and 
females at serial measurement during and after anticoagula-
tion withdrawal is shown in Fig. 1. The peak of the first posi-
tive result occurred at day 15 test. Positive results were more 
frequent in men than in women at all time-points, though 
the difference reached statistical significance only at 60-day 
control (p = 0.014). A late first positive D-dimer result was 
recorded (at T60 or T90 serial assessment) in 37 males and 
12 females (29.4% and 19.3% of all patients with positive 
results, respectively). In women, but not in men, age was 
significantly higher in subjects with positive D-dimer results 
(p = 0.001). Both in men and women, the rates of positive 
D-dimer were not statistically different whether the index 
event was idiopathic or associated with WRF (males: idi-
opathic = 46.6%, WRF = 43.7%; females: idiopathic = 36.5%, 
WRF = 27.8%; differences not statistically significant).
All patients with negative D-dimer results (n. 287) were 
advised to stop anticoagulant treatment, whereas those with 
positive results (n. 188) were recommended to continue or 
resume anticoagulation with a VKA (warfarin in all cases), 
at the time the only type of oral anticoagulant drug avail-
able. Five recurrent VTE events occurred in 2-year follow-
up in patients who had persistently negative D-dimer results 
(Table 4), with an incidence of 1.7% patient-years (95% CI 
0.5–4.5) in males and 0.4% patient-years (95% CI 0–2.5) 
in females. In contrast, 8 recurrent events occurred among 
the 59 patients who refused to resume anticoagulation after 
positive D-dimer results, with an incidence of 7.3% patient-
years (95% CI 2.8–16.5) and 11.5% patient-years (95% 
CI 3.2–29.8) in males and females, respectively. Of the 8 
recurrent events, 4 occurred in patients whose first positive 
D-dimer result was obtained at T15, 3 at T30 and one event 
in a patient with positive D-dimer at T60.
In women with an index event that was HCT-related, 
one recurrent event occurred among the 89 with negative 
D-dimer, and one among the 11 with positive results who 
stayed without anticoagulation. The Kaplan–Meier curves 
of cumulative primary efficacy outcomes in males/females 
with persistently negative D-dimer results stopping antico-
agulation and positive D-dimer results refusing to resume 
anticoagulation are shown in Fig. 2. Hazard ratios for occur-
ring outcomes were significantly higher, though with wide 
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confidence intervals, in males and females with positive 
D-dimer results than in corresponding subjects with nega-
tive results [HR 4.15 (95% CI 1.16–14.8), and 28.2 (95% 
CI 3.12–254), respectively]. Vice versa, HR was not sig-
nificantly different between male or female subjects with 
positive [1.76 (95% CI 0.48–6.50)] or negative [3.86 (95% 
CI 0.44–26.1)] D-dimer results (Fig. 2).
Discussion
The present report shows that in non-elderly patients (aged 
up to 65 years) with VTE either unprovoked or associated 
with weak risk factors, serial D-dimer measurements can 
reliably be used to assess individual risk of recurrence and 
manage the duration of anticoagulation irrespective of gen-
der. All patients with positive D-dimer results were encour-
aged to resume anticoagulation so as to prevent recurrent 
events and reduce the number of subjects with repeatedly 
negative D-dimer in whom the rate of recurrent VTE was 
found to be very low in both genders. Indeed, anticoagula-
tion was safely stopped in 53.7% of males and 69.5% of 
females due to negative D-dimer results. The incidence of 
subsequent recurrence was very low: 1.7% and 0.4% patient-
years in males and females, respectively, the upper limits of 
95% confidence intervals being < 5% (a level of risk that is 
considered acceptable to stop anticoagulation) [18] in both 
genders.
Our D-dimer procedure resulted more frequently positive 
in men than in women. Besides the significantly older age 
of males, we believe this result can mainly be accounted 
for by the lower D-dimer cut-off levels adopted in our 
study in males versus females. This approach was intended 
to identify more males at potentially higher risk of recur-
rent VTE and extend anticoagulation in them. There is, in 
fact, general agreement that males are at a higher risk of 
recurrent VTE events than females [2–4, 19]. Male sex is 
included as a relevant risk factor in virtually all algorithms 
designed to identify individual risk of recurrent VTE [5, 
6]. One prediction rule, incorporating D-dimer testing only 
during anticoagulation, concluded that the proposed rule was 
useless in men since all needed indefinite anticoagulation 
[7]. The first-time-ever positive D-dimer results were more 
prevalent in men than in women at all serial measurements 
Table 2  Baseline characteristics 
of the 475 study patients
DVT proximal vein thrombosis, IQR interquartile range, PE pulmonary embolism, RVT residual vein 
thrombosis, VTE venous thromboembolism
Male Female p value
N (%) 272 (57.3) 203 (42.7)
Age (years), median (IQ) 54 (45–61) 43 (34–51) < 0.0001
Type of VTE, n (%)
 DVT 147 (54.0) 95 (46.8) 0.121
 DVT + PE 69 (25.4) 38 (18.7) 0.084
 Isolated PE 56 (20.6) 70 (34.5) 0.001
Type of risk factors, n (%)
 Idiopathic 240 (88.2) 63 (31.0) < 0.0001
 Weak risk factors 32 (11.8) 140 (69.0) < 0.0001
  Minor general, laparoscopic, or arthroscopic surgery 1 3
  Pregnancy or puerperium 0 4
  Hormonal contraceptive/replacement therapy 0 120/3
  Long travel 5 6
  Minor trauma, leg injury, reduced mobility 19 13
  Hospitalization in a medical ward 8 7
Duration of previous anticoagulation, n (%)
 ≤ 6 months 89 (32.8) 69 (34.0) 0.784
 7–12 months 147 (54.0) 112 (55.2) 0.795
 > 12 months 36 (13.2) 22 (10.8) 0.429
Total duration of follow-up for all patients (years) 435 348
Follow-up (years), median (IQ) 1.95 (1.30–2.00) 2.00 (1.51–2.00) 0.048
Patients censored during follow-up, n (%) 23 (8.5) 7 (3.4) 0.024
Lost to follow-up, n (%) 1 (0.4) 1 (0.5) 0.871
Presence of RVT (> 4 mm), n (%) 37 (13.6) 6 (3.0) 0.0001
Associated antiplatelet treatment, n (%) 16 (5.9) 2 (1.0) 0.006
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with a difference that reached statistical significance at T60, 
while the rate of first positive results dropped dramatically in 
women (see Fig. 1). The fact that males, more than females, 
may present signs of hypercoagulability at a later date, a 
condition possibly associated with a risk of VTE recurrence, 
confirms the importance of a serial D-dimer determination, 
especially in men.
The performance of D-dimer testing in our study as 
predictor of risk for VTE recurrence was very good, 
helping to distinguish subjects at low or high risk in both 
women and in men. The good results obtained with our 
D-dimer procedure are probably due to the cutoff values 
we adopted, values which in males were generally lower 
than those recommended by manufacturers for diagnos-
tic procedures and lower than those used for women who 
physiologically have higher D-dimer values than men [5, 
20]. As a consequence, more male (46.3%) than female 
(30.5%, p = 0.001) patients had positive D-dimer results 
Table 3  Baseline characteristics of the patients with negative/positive D-dimer results
a These percentages are calculated versus the 120 women whose VTE event occurred during HCT
DVT proximal vein thrombosis, HCT hormonal contraceptive therapy, IQR interquartile range, PE pulmonary embolism, RVT esidual vein 
thrombosis, VTE venous thromboembolism, WRFs weak risk factors
Males (n = 272) p value Females (n = 203) p value p value for positive 
D-dimer in males vs 
femalesNegativeD-dimer
Positive
D-dimer
Negative
D-dimer
Positive
D-dimer
n (%) 146 (53.7) 126 (46.3) 141 (69.5) 62 (30.5) 0.001
Age (years), median (IQR) 53 (45–61) 55 (48–62) 0.120 40 (32–48) 48 (39–55) 0.001 < 0.0001
Type of VTE, n (%)
 DVT 82 (56.2) 65 (51.6) 0.449 70 (49.6) 25 (40.3) 0.222 0.146
 DVT + PE 35 (24.0) 34 (27.0) 0.571 24 (17.1) 14 (22.6) 0.357 0.517
 Isolated PE 29 (19.8) 27 (21.4) 0.745 47 (33.3) 23 (37.1) 0.601 0.022
Type of risk factors, n (%)
 Idiopathic 128 (87.7) 112 (88.9) 0.760 40 (28.2) 23 (37.1) 0.218 < 0.0001
 WRFs 18 (12.3) 14 (11.1) 0.760 101 (71.6) 39 (62.9) 0.218 < 0.0001
 (Total HCT n = 120; n; %) (89; 74.2a) (31; 25.8a) 0.081
Total duration of follow-up for all patients 
(years)
234 201 241 107
Patients censored during follow-up, n (%) 11 (7.5) 12 (9.5) 0.554 3 (2.1) 4 (6.4) 0.121 0.474
Lost to follow-up, n (%) 1 (0.7) 0 (0) 0.348 0 (0) 1 (1.6) 0.133 0.156
Presence of RVT (> 4 mm), n (%) 18 (12.3) 19 (15.1) 0.502 3 (2.1) 3 (4.8) 0.294 0.039
Associated antiplatelet treatment, n (%) 10 (6.8) 6 (4.8) 0.485 2 (1.4) 0 (0) 0.350 0.080
Fig. 1  Prevalence of first-
time-ever positive D-dimer 
results in males/females at the 
serial measurement days after 
anticoagulation withdrawal 
(the percentages are calculated 
vs the total number of patients 
included)
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and resumed anticoagulation with subsequent protection 
against recurrence risk.
Another factor informing the good results obtained with 
our procedure was serial D-dimer measurement which, fol-
lowing a previous study of our group [21], covered the first 
three months after anticoagulation suspension. Repeated 
D-dimer measurement allowed detection of several patients 
developing signs of hypercoagulability very early (T15) or 
later than 30 days (T30, that is the generally used timing 
assessment [4]) after anticoagulation interruption. In fact, 
29.4% of males and 19.5% of female patients had their first 
positive D-dimer results 60 or 90 days after anticoagula-
tion was interrupted. Furthermore, among the patients who 
refused to resume anticoagulation, recurrent VTE occurred 
in 3 patients with a first positive D-dimer at T15 and in 
one with positive D-dimer at T60. These results confirm 
the importance of serial D-dimer assessment in helping to 
reduce the risk of recurrence either early after anticoagu-
lation is stopped or in subjects who present late signs of 
hypercoagulability.
The index event was unprovoked in the vast majority of 
males (88.2%), but only in 31.0% of women (p < 0.0001). 
It seems reasonable to ascribe this difference to the effect 
of the large number of women (n. 120) included for HCT-
related index event. The prevalence of positive D-dimer 
results was not statistically different in males and females 
whose index event was either unprovoked a or associated 
with weak risk factors. These results demonstrate that a con-
dition of hypercoagulability may occur after anticoagulation 
is stopped in subjects of both sexes whose index event was 
either idiopathic or WRF-related and that D-dimer test-
ing helps to identify these subjects. In particular, it can be 
noticed that among the 120 women included in the study 
following HCT-related VTE event, a condition generally 
regarded as being at low risk of recurrence [6, 22], our 
D-dimer procedure allowed identification of some subjects 
(about 25%) with positive testing in whom the risk of recur-
rence was non-negligible as shown by the single PE recur-
rence case that occurred during follow-up among the 11 with 
positive D-dimer who did not resume anticoagulant therapy.
In contrast with our results, other studies have not found 
negative D-dimer results safe enough for stopping anti-
coagulation, especially in men. Rodger et al. [3] assessed 
D-dimer levels while patients were still on warfarin, using 
the quantitative Vidas D-dimer reagent (bio-Mérieux) with 
cutoff level for positive results set at ≥ 250 ng/mL (half the 
Table 4  Clinical events occurred during follow-up in the investigated patients
DVT proximal deep vein thrombosis, PE pulmonary embolism, SVT superficial vein thrombosis
a No death could be attributed to thrombotic event
Negative D-dimer Positive D-dimer, without anticoagulation Positive D-dimer, with antico-
agulation
Male
n = 146
Female
n = 141
Male
n = 44
Female
n = 15
Male
n = 82
Female
n = 47
Duration of follow-up 
(years)
234 241 68 26 133 81
VTE recurrences during 
follow-up, n (%; 95% 
CI) (in women with 
HCT-associated index 
event)
4 (2.7; 0.8–7.1) 1 (0.7; 0–4.3) (1/89) 5 (11.4; 4.5–24.4) 3 (20.0; 6.3–46.0) (1/11) 1 (1.2; 0–7.2) 0 (0/20)
Incidence per 100 pt-y, 
% (95% CI)
1.7 (0.5–4.5) 0.4 (0–2.5) 7.3 (2.8–16.5) 11.5 (3.2–29.8)
Type of event, n
 DVT 3 1 5 1 0 0
 PE 1 0 0 1 1 0
 DVT + PE 0 0 0 1 0 0
Other outcomes, n
 Deatha 0 0 0 0 0 0
 Isolated distal DVT 2 1 2 0 0 0
 SVT 4 1 1 0 1 0
 Arterial vascular event 1 0 0 0 0 0
Major bleeding, n (%; 
(95% CI)
0 0 0 0 2 (2.4; 0.1–9.0) 1 (2.1; 0–12.1)
Incidence per 100 pt-y 
(95% CI)
1.5 (0–5.7) 1.2 (0–7.3)
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value adopted for VTE exclusion with that assay). They 
found that positive D-dimer results were associated with 
higher recurrence risk in women but not in men. D-dimer 
assessment performed only while patients were on antico-
agulants makes the results of this study hard to compare 
with those of all other studies on the issue. It is reasonable 
to surmise that a potential condition of hypercoagulability 
(and higher D-dimer levels) is effectively counteracted with 
effective anticoagulation but may come back in play when 
anticoagulants are stopped. This effect is clearly shown in 
Fig. 1 of the present report, where it can be seen that the rate 
of positive D-dimer is very low during anticoagulation but 
increases sharply at the following time-points, till 60 days 
and more after anticoagulation was interrupted.
More recently, Kearon et al. [10] assessed D-dimer lev-
els twice, once during anticoagulation and the other one 
month after its withdrawal, in a cohort of 410 patients who 
had a first unprovoked VTE event. They used a qualitative 
assay (Clearview Simplify, by Alere), a point-of-care assay 
intended to give positive or negative results via calibration 
versus diagnostic level for VTE exclusion. Anticoagulant 
therapy was definitively stopped in 319 patients after 2 
negative D-dimer results; their rate of recurrent VTE was 
6.7% (95% CI 4.8% to 9.0%) per patient-year, higher in 
men (9.7% (CI 6.7–13.7%). The authors concluded that 
“The risk for recurrence in patients with a first unprovoked 
VTE who have negative D-dimer results is not low enough 
to justify stopping anticoagulant therapy in men…”. We 
believe that these disappointing results were mainly due 
to the extremely low rate of positive results (only 16.8% of 
the whole patient cohort), with a subsequent high propor-
tion of patients not resuming anticoagulation and a high 
rate of VTE recurrence in these patients. In contrast, most 
studies on the issue have pointed to a much higher rate of 
patients with positive D-dimer results. Post-anticoagula-
tion D-dimer results were positive in 45.4% of patients in a 
patient-level meta-analysis [4], and in 36.5% of patients in 
the present analysis involving patients aged up to 65 years. 
The qualitative D-dimer assay used in Kearon’s study 
(Clearview Simplify) was the same as the one we used 
in the PROLONG study published in 2006, in which the 
rate of positive results was more than twice (36.7%) that 
recorded in Kearon’s study [8]. However, the manufactur-
ers of D-dimer assays used in the studies were different: 
Alere in the Kearon’s study and Inverness Medical Profes-
sional Diagnostics in the PROLONG study. A different 
sensitivity of the two assays cannot be excluded, and was 
probably lower in the case of Alere assay, thus explain-
ing the particularly high number of patients with negative 
D-dimer results in the Kearon study and the subsequent 
Fig. 2  Kaplan–Meier cumulative event rates for the primary efficacy outcome in males/females with persistently negative D-dimer results in 
whom anticoagulation was definitively stopped and in males/females with positive D-dimer results who refused to resume anticoagulation
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relatively high incidence of recurrent events in the patients 
who did not resume anticoagulant treatment.
Our study has several limitations. Firstly, our conclusions 
can only be applicable in individuals aged 65 years or less. 
Since D-dimer levels increase sharply with age [13], it is 
very difficult to define age-appropriate cutoff values and to 
identify possible different risks of recurrence among older 
individuals, as confirmed in the recent validation study of 
the DASH score which failed to be risk-predictive in elderly 
patients [14]. Furthermore, it should not be forgotten that 
some elderly VTE patients may be at a higher risk of bleed-
ing while on anticoagulant therapy and so may benefit from 
discontinuing anticoagulation after the first months irrespec-
tive of the nature of their VTE [15]. A population-based 
observational study [23] recorded incidence rates of major 
bleeding episodes of 13.2% in subjects aged ≥ 65 years ver-
sus 6.6% in those aged < 65 years, after 1 year of follow-up 
(p < 0.001), with 77% of bleeding events occurring dur-
ing anticoagulation [24]. This confirmed the higher risk of 
bleeding in VTE subjects aged 65 years or more. Secondly, 
the inclusion of patients with HCT-related VTE may be 
questioned, as the risk of recurrent events is low provided 
hormonal therapy is definitively discontinued [6, 25]. We 
considered hormonal therapy a weak risk factor for VTE 
and so included these patients in the study as well as those 
with different weak risk factors. Moreover, since negative 
D-dimer findings will be markedly prevalent in this popula-
tion they can be seen as a useful factor for reassuring women 
to stop anticoagulation, while the few with positive results 
can be more carefully informed of their risk and so may be in 
a better condition to decide what to do next. Thirdly, we are 
aware that serial D-dimer assessments in the first 3 months 
after anticoagulation interruption may be inconvenient for 
both patients and physicians and may generate confusion in 
professionals, especially in case of a suspected VTE recur-
rence during the period. However, we are convinced that 
D-dimer assessment should be extended beyond 1 month 
after anticoagulation is interrupted to detect patients with 
late onset of signs of hypercoagulability who still may have a 
non-negligible risk of recurrence. Finally, all the mentioned 
studies were performed in patients who received vitamin K 
antagonists as anticoagulant drug. Results of a recent study 
suggest that D-dimer levels can change differently, either 
during or after anticoagulation is discontinued, when direct 
oral anticoagulants are used for anticoagulation treatment 
in VTE patients [26].
In conclusion, the present sub re-analysis of data col-
lected in the DULCIS study [12] suggests that in both 
male and female patients aged up to 65 years with a first 
VTE event unprovoked or associated with weak risk fac-
tors, the adoption of serial D-dimer assessment (using 
sensitive quantitative assays, with specifically established 
cutoff values to indicate negative/positive results) may 
help attending physicians to evaluate the individual risk 
of recurrence and decide whether to extend or discontinue 
anticoagulation.
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